Inari Medical, Inc. (NASDAQ:NARI) Director Sells $12,094,000.00 in Stock

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 200,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $60.47, for a total value of $12,094,000.00. Following the transaction, the director now directly owns 238,987 shares in the company, valued at $14,451,543.89. The trade was a 45.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

William Hoffman also recently made the following trade(s):

• On Monday, December 16th, William Hoffman sold 60,000 shares of Inari Medical stock. The stock was sold at an average price of $55.66, for a total value of $3,339,600.00.
• On Monday, November 18th, William Hoffman sold 60,000 shares of Inari Medical stock. The shares were sold at an average price of $51.16, for a total value of $3,069,600.00.
• On Tuesday, October 29th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $50.05, for a total transaction of $2,002,000.00.
• On Wednesday, October 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00.

Inari Medical Stock Performance

Shares of NASDAQ:NARI opened at $79.30 on Thursday. The firm has a market cap of $4.64 billion, a PE ratio of -58.74 and a beta of 0.97. The firm’s 50 day simple moving average is $52.85 and its 200-day simple moving average is $48.92. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $79.69.

Hedge Funds Weigh In On Inari Medical

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its position in shares of Inari Medical by 67.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after acquiring an additional 473 shares in the last quarter. KBC Group NV raised its position in shares of Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after purchasing an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after purchasing an additional 522 shares in the last quarter. Covestor Ltd grew its position in Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after purchasing an additional 926 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Inari Medical during the 2nd quarter valued at approximately $104,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on NARI shares. Baird R W lowered shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. William Blair reiterated a “market perform” rating on shares of Inari Medical in a research report on Tuesday. BTIG Research restated a “neutral” rating on shares of Inari Medical in a report on Wednesday. Stifel Nicolaus started coverage on Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 target price for the company. Finally, Wells Fargo & Company reissued an “equal weight” rating and issued a $80.00 price objective (up from $65.00) on shares of Inari Medical in a research note on Tuesday. Twelve research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $68.00.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.